Pancreatic Carcinoma

KRAS G12/G13 status was evaluated in cell-free DNA (cfDNA) of patients with untreated metastatic adenocarcinoma of the pancreas that were randomised (1:1) to receive gemcitabine plus trametinib or pla… (full text at CIViC)

PMID 24915778 · Infante et al., 2014 · Open in CIViC

Inhibition of ERK in 11 KRAS mutant pancreatic cancer cell lines with SCH772984 was more effective than MEK Inhibition. Combined Treatment with PI3K Inhibitor AZD8186 was more effective than either ag… (full text at CIViC)

PMID 26725216 · Hayes et al., 2016 · Open in CIViC

In this case report, a 66-year old woman with pancreatic ductal adenocarcinoma was treated with trametinib for a BRAF in-frame-deletion and TP53 mutation and achieved an initial partial response for c… (full text at CIViC)

PMID 29903880 · Aguirre et al., 2018 · Open in CIViC

In this case report, a 66-year old woman with pancreatic ductal adenocarcinoma was treated with trametinib for a BRAF in-frame-deletion and TP53 mutation and achieved an initial partial response for c… (full text at CIViC)

PMID 29903880 · Aguirre et al., 2018 · Open in CIViC

In preclinical pancreatic ductal adenocarcinoma (PDAC) models with high NQ01 expression, which indicates the NFE2L2 (NRF2) pathway activation, the small molecule NSC84167 (NSLC01, 50 mg/kg) selectivel… (full text at CIViC)

PMID 34247201 · Dai et al., 2021 · Open in CIViC

In pancreatic cancer cell lines MiaPaCa2 and Panc1, gemcitabine 1 μmol/L induced NR4A2/NURR1 expression and triggered cytoprotective autophagy, while both CRISPR-mediated NR4A2 knockout and the NR4A2 … (full text at CIViC)

PMID 35582016 · Zarei et al., 2021 · Open in CIViC

In a retrospective TCGA PDAC (tumors n = 179, normals n = 171), high ATG7 expression was significantly associated with poorer survival on Kaplan–Meier analysis (P = 0.013), and high ATG12 expression s… (full text at CIViC)

PMID 35582016 · Zarei et al., 2021 · Open in CIViC

A patient with pancreatic ductal adenocarcinoma (PDAC) and a somatic PALB2 mutation (NM_024675.4: c.3350+1G>T) experienced disease progression after 10 cycles of FOFIRINOX and 2 cycles of gemcitabine.… (full text at CIViC)

PMID 36119518 · Kachmazov et al., 2022 · Open in CIViC

Among 33 patients treated with pan-AKT inhibitor MK-2206 in this phase 1 study, one patient with pancreatic adenocarcinoma and PTEN loss/KRAS G12D mutation experienced a decrease of approximately 60% … (full text at CIViC)

PMID 22025163 · Yap et al., 2011 · Open in CIViC

In Capan-1 cell lines engineered to reduce pRB expression (by transfection with p16), resensitization to chemotherapy-induced apoptosis was observed. The effect was asserted to be specific to pRB depl… (full text at CIViC)

PMID 11792751 · Plath et al., 2002 · Open in CIViC

Surgically resected PDACs were used to create tissue microarrays, which were scored for antibody staining of hENT1 (SLC29A1). For patients treated with gemcitabine (n=243), high levels of hENT1 were a… (full text at CIViC)

PMID 22705007 · Maréchal et al., 2012 · Open in CIViC

In this case report of a single patient with pancreatic adenocarcinoma was found to harbour a SLC4A4::ROS1 fusion by NGS analysis. Based on the presence of the ROS1 fusion the patient was initiated on… (full text at CIViC)

PMID 37079858 · Reutter et al., 2023 · Open in CIViC

In 249 patients that have undergone a pancreaticoduodenectomy (Whipple) for the resection of pancreatic ductal adenocarcinoma, expression of SMAD4 is associated with favorable prognosis. SMAD4 was ass… (full text at CIViC)

PMID 11751510 · Tascilar et al., 2001 · Open in CIViC

In a study of 89 patients with adenocarcinoma of the pancreas who underwent a pancreaticoduodenectomy, those with mutations in SMAD4 had shorter overall survival than wild-type patients.

PMID 19584151 · Blackford et al., 2009 · Open in CIViC

In a preclinical study using STK11/LKB1-deficient pancreatic ductal adenocarcinoma (PDAC) cell lines (TB 32047, PANC-1, SUIT2, SU86.86, KPC792) and C57BL/6 orthotopic mouse models (n = 5 per group), t… (full text at CIViC)

PMID 38461159 · Zhang et al., 2024 · Open in CIViC

In patients with KRAS wild-type (KRASwt) tumors druggable gene fusions have been identified. These alterations included recurrent NRG1 rearrangements predicted to drive PDAC development through aberra… (full text at CIViC)

PMID 29802158 · Heining et al., 2018 · Open in CIViC

In patients with KRAS wild-type (KRASwt) tumors druggable gene fusions have been identified. These alterations included recurrent NRG1 rearrangements predicted to drive PDAC development through aberra… (full text at CIViC)

PMID 29802158 · Heining et al., 2018 · Open in CIViC